Head & Neck Cancers | Clinical

Survival in Advanced ESCC Improved With Frontline Nivolumab Plus Ipilimumab or Chemotherapy

July 22, 2021

Improved survival outcomes were reported with the addition of nivolumab to either ipilimumab or chemo-therapy vs chemotherapy alone in the frontline treatment of patients with unresectable advanced or meta-static esophageal squamous cell carcinoma.

JAVELIN HEAD AND NECK 100 Informs Future Trials in HNSCC

June 26, 2021

The potential benefit of avelumab in the subgroup of patients with high PD-L1 expression in JAVELIN HEAD AND NECK 100 provides a basis for further investigation and suggests a potential role for immune checkpoint inhibitors for locally advanced HNSCC.

Tislelizumab Prolongs PFS in Recurrent or Metastatic Nasopharyngeal Cancer

May 21, 2021

Tislelizumab, an anti-PD-1 antibody combined with gemcitabine and cisplatin demonstrated improvement in progression-free survival (PFS) compared with chemotherapy as first-line treatment of patients with recurrent or metastatic nasopharyngeal cancer, meeting the primary end point of the phase 3 RATIONALE 309 trial, according to a press release by BeiGene, Ltd.

Further Research Needed to Support Use of Checkpoint Inhibitors in Locally Advanced HNSCC

May 06, 2021

Avelumab was explored in a clinical trial for the treatment of locally advanced head and neck squamous cell carcinoma, but more research is needed to position the agent and other checkpoint inhibitors in the treatment landscape, experts say.

Tipifarnib Elicits Encouraging Responses in Patients With Recurrent or Metastatic HNSCC

April 27, 2021

Results from the phase 2 study of farnesyltransferase inhibitor tipifarnib showed significant responses in patients with recurrent and/or metastatic head and neck squamous cell carcinoma and demonstrated that variant alle frequency could be a potential biomarker in this patient population.